Basilea lands BARDA contract for ceftobiprole

Basilea Pharmaceutica AG (SIX:BSLN) said HHS's Biomedical Advanced Research and Development Authority awarded it a 4.5-year contract potentially worth

Read the full 196 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE